Download Files:

Verosudil

$110$520

Products Details

Product Description

– Verosudil (AR-12286) is a potent, selective Rho-kinase (ROCK) inhibitor with Kis of 2 and 2 nM for ROCK1 and ROCK2, respectively. AR-12286 lowers intraocular pressure (IOP) primarily by increasing aqueous humour outflow through the trabecular meshwork[1][2].

Web ID

– HY-16758

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C17H17N3O2S

References

– [1]Kopczynski C, Novack GD, Swearingen D, van Haarlem T. Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers. Br J Ophthalmol. 2013;97(5):567‐572.|[2]Lin CW, Sherman B, Moore LA, et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2018;34(1-2):40‐51.

CAS Number

– 1414854-42-4

Molecular Weight

– 327.40

Compound Purity

– 99.66

SMILES

– O=C(NC1=CC2=C(C(NC=C2)=O)C=C1)C(N(C)C)C3=CSC=C3

Clinical Information

– Phase 2

Research Area

– Neurological Disease

Solubility

– DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– ROCK

Isoform

– ROCK1;ROCK2

Pathway

– Cell Cycle/DNA Damage;Cytoskeleton;Stem Cell/Wnt;TGF-beta/Smad

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.